Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

GRIFOLS BIO SUPPLIES INC.

UEI: G2J3B2DKC4J2CAGE: 3J273

GRIFOLS BIO SUPPLIES INC. is a federal contractor, registered under UEI G2J3B2DKC4J2 and CAGE code 3J273. It has been awarded $542,827 in federal contracts. Primary work spans Blood and Organ Banks, Unknown NAICS, and In-Vitro Diagnostic Substance Manufacturing. Top awarding agencies include Department Of Health And Human Services and Department Of Defense.

Contact Information

Registration and classification details

Registration

UEI Code

G2J3B2DKC4J2

CAGE Code

3J273

Entity Structure

Corporate Entity (Not Tax Exempt)

Established

N/A

Business Classifications

For Profit Organization

NAICS Codes

325413In-Vitro Diagnostic Substance Manufacturing
621991Blood and Organ Banks(Primary)

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

Grifols Bio Supplies Inc. specializes in the manufacturing and supply of human blood products and in-vitro diagnostic substances, with a focused expertise in leuko-reduced packed red blood cells prepared in ACD and CPD anticoagulant solutions. The company delivers clinically critical blood component...

Grifols Bio Supplies Inc. specializes in the manufacturing and supply of human blood products and in-vitro diagnostic substances, with a focused expertise in leuko-reduced packed red blood cells prepared in ACD and CPD anticoagulant solutions. The company delivers clinically critical blood components under strict apheresis and blood banking protocols, ensuring compliance with FDA and AABB standards for sterility, viability, and antigen compatibility. Their technical capabilities include leukoreduction filtration, cold chain logistics, unit labeling, and just-in-time distribution of O-positive and other blood group-specific units, tailored for transfusion medicine applications in hospital and emergency response settings. A key differentiator is their precision in fulfilling complex, time-sensitive requirements for specialized blood products used in trauma, surgical, and immunocompromised patient care. The contractor maintains a consistent relationship with the Department of Health and Human Services, primarily supporting federal health programs requiring reliable access to human blood derivatives and diagnostic-grade biological materials. Their work supports public health infrastructure, including blood bank operations for federal medical facilities and emergency preparedness initiatives. Grifols Bio Supplies operates primarily within NAICS 325413 (in-vitro diagnostic substance manufacturing) and 621991 (blood and organ banks), positioning itself as a niche supplier in the transfusion medicine supply chain. The company serves the biomedical and clinical diagnostics vertical by bridging manufacturing and direct clinical delivery of blood components, filling a critical gap between centralized blood collection and end-user hospital systems. As a 2L entity based in Los Angeles, California, Grifols Bio Supplies Inc. functions as a specialized distributor and manufacturer without current federal certifications. Their geographic presence enables efficient distribution across western U.S. federal healthcare networks, supporting mission-critical blood product procurement needs with a focus on regulatory adherence and operational reliability.

Key Performance Metrics

Awards Count

32

All time

Active

0

Currently performing

Completed

32

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency
Awards by NAICS
Awards by Agency Over Time
Awards by Place of Performance

Compete with GRIFOLS BIO SUPPLIES INC.

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for GRIFOLS BIO SUPPLIES INC.

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS

Open opportunities in GRIFOLS BIO SUPPLIES INC.'s top NAICS codes and agencies

NAICS: 325413
New
DIBBS
CULTURE MEDIUM, THAYER-
Solicitation # SPE2DS-27-T-1066
Solicitation SPE2DS-27-T-1066 is a request for quotations issued by the DLA Troop Support Medical Supply Chain for the procurement of one package of Thayer-Martin Modified (MTM II) Agar culture medium, identified by NSN 6550-01-711-1542. This dark brown, ready-to-use plated medium is specifically designed for the isolation of pathogenic Neisseria from specimens containing mixed flora of bacteria and fungi. The product is delivered in packages of 100 plates and requires strict refrigeration storage between 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit) and must not be frozen. The contract mandates a non-extendable shelf life of three months, with a requirement that no more than 14 days elapse between the date of manufacture and the date of delivery to the government. Delivery is set for JBER, Alaska, with a required delivery date of October 27, 2026, under FOB Destination terms. Packaging must be commercial and sealed to prevent damage, with marking adhering to Medical Marking Standard No. 1 and shelf-life labels following MMS1C. Administrative requirements include electronic invoicing via the Wide Area WorkFlow system and compliance with various FAR and DFARS clauses, including the Buy American Act, Berry Amendment, and safeguarding of covered defense information. Evaluation will consider technical data for any alternate products offered and may include HUBZone price evaluation preferences. Inspection and acceptance will occur at the destination.
MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

about 21 hours ago

DEADLINE

in 5 days
View Details
NAICS: 541330
New
Federal
AIR FORCE CRYPTOLOGIC OFFICE COMMERCIAL SOLUTIONS OPENING
Solicitation # FA7037-21-S-C001
The Air Force Cryptologic Office (AFCO) Cyberspace Intelligence Surveillance and Reconnaissance and Multi-Domain Innovation Division is soliciting innovative commercial capabilities through Commercial Solutions Opening FA7037-21-S-C001. The agency is seeking mature technologies and innovative services in Electromagnetic Warfare, Information Operations, and electromagnetic digital communications, with a specific goal of achieving a field demonstration within one year. The procurement process is divided into two phases: Phase I requires the submission of a quad chart and a white paper, while Phase II consists of full proposals by invitation only. Awards may be issued as traditional contracts or Other Transactions (OT), with potential funding ranging from 50,000 dollars to 50 million dollars over a period of performance lasting between one and five years. The evaluation process is based on technical merit, importance to agency programs, and fund availability, utilizing peer or scientific review to select offerors. Successful projects are expected to follow a structure of base period tasks to demonstrate feasibility, followed by option tasks for design, fabrication, testing, and evaluation. Because the work supports DoD ISR-Cyber capabilities, offerors must possess the necessary personnel and facility security clearances to handle classified work independently. All acquired technologies are treated as commercial items under 10 USC 3458 and DFARS 212.70. Submissions are managed by Carissa Heuertz, and the performance location is identified as San Antonio, Texas.
Department Of Defense

POSTED

1 day ago

DEADLINE

in 11 months
View Details
NAICS: 325413
New
Federal
6550--Optilite analyzer reagents
Solicitation # 36C26227Q0052
The Department of Veterans Affairs, Southern Arizona Healthcare System, is soliciting a Firm-Fixed Price Blanket Purchase Agreement under solicitation 36C26227Q0052 for the procurement of FDA-approved reference testing reagents and consumables validated for use on the Optilite analyzer. The scope includes specific items such as Freelite Kappa, Freelite Lambda, and Ceruloplasmin reagents, as well as TENCELL cuvettes and sample cups. To ensure system performance and safety, all materials must be manufactured by Binding Site Laboratories, and substitutions are prohibited. The contract is issued as a full and open competition under NAICS code 325413, with a total estimated period of performance of sixty months, consisting of a base period from November 9, 2026, to November 8, 2027, followed by four one-year option periods. The award will be granted to the responsible offeror whose proposal is most advantageous to the government, based on a technical acceptability review of the Statement of Work and the lowest price. Deliveries are required to be made to various VA Medical Centers across Arizona, California, and New Mexico, with standard orders delivered within four working days of placement. All shipments must be destination-based, with the vendor assuming all shipping costs and adhering to strict packaging standards to prevent damage. Invoicing is handled electronically through the Department of Veterans Affairs Financial Services Center in accordance with the Prompt Payment Act. Quotes must be submitted via email to Contract Specialist Carlos Magana by November 4, 2026.
262-NETWORK Contract Office 22 (36C262)

POSTED

2 days ago

DEADLINE

in 6 days
View Details
NAICS: 325414
New
Federal
Foot and Mouth Disease (FMD) Vaccine Antigen Concentrate (VAC)
Solicitation # 12639527R0001
Solicitation 12639527R0001 is a request for proposal issued by the USDA Animal and Plant Health Inspection Service (APHIS) for an unrestricted, IDIQ contract focused on Foot and Mouth Disease (FMD) Vaccine Antigen Concentrate (VAC). The scope of work includes the purchase and storage of VAC, the conversion of Government-owned VAC into usable finished vaccines, and the direct purchase of finished vaccines. The contract features a ceiling price of 800 million dollars and a long-term performance horizon, consisting of five one-year ordering periods for VAC and direct purchases starting December 1, 2026, with conversion and delivery of finished vaccines extending through November 30, 2044. The contractor is required to produce VAC with a minimum capacity of 1.0 million doses and maintain storage on their premises under strict quality control and temperature monitoring standards. Due to the nature of the material, live FMDV is classified as a Tier 1 Select Agent, requiring specific authorization from the CDC/APHIS and adherence to rigorous shipping and security restrictions. Award will be based on the most advantageous offer, evaluating technical capability, past performance, and price, with technical and past performance factors weighted equally. Proposals must be submitted electronically in four separate volumes by November 10, 2026.
Mrpbs Minneapolis Mn

POSTED

2 days ago

DEADLINE

in 12 days
View Details